Crescent Biopharma Reports $24.8 Million Net Loss and Initiates Global Trials for CR-001

Crescent Biopharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $24.8 million for the quarter, compared to a loss of $21.8 million in the same period last year. For the first half of 2026, the net loss totaled $48.1 million, up from $36.9 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which rose to $19.4 million for the quarter, a 60% increase from $12.1 million in the previous year. General and administrative expenses remained relatively stable, totaling $8.7 million for the quarter, slightly down from $8.9 million in the prior year.

Crescent Biopharma's revenue for the quarter was negligible, with a modest $1.0 million generated from a license agreement with Kelun for the six months ended June 30, 2026. This marks the company's first revenue recognition, reflecting the initial supply of its CR-001 product. The company has not yet generated revenue from product sales and does not anticipate doing so in the near future, as it remains focused on advancing its clinical development programs.

The company has made strategic advancements, including the initiation of a global Phase 1/2 trial for its lead product candidate, CR-001, which is designed to target solid tumors. Additionally, Crescent Biopharma has entered into a partnership with Kelun to develop SKB105, an integrin beta-6-directed antibody-drug conjugate, outside of Greater China. The company is also preparing to initiate a Phase 1/2 trial for CR-002, another product candidate, in the second half of 2026.

As of June 30, 2026, Crescent Biopharma reported cash and cash equivalents of $171.6 million, a decrease from $213.2 million at the end of 2025. The company utilized $28.4 million in operating activities during the first half of 2026, primarily due to its ongoing research and development efforts. The company expects its existing cash reserves, along with proceeds from a recent public offering, to be sufficient to fund operations for at least the next twelve months. However, it acknowledges the need for additional financing to support its development programs and achieve commercialization of its product candidates.

Looking ahead, Crescent Biopharma anticipates continued investment in its research and development activities, with a focus on advancing its clinical trials and expanding its product pipeline. The company remains committed to its goal of developing innovative therapies for cancer treatment, while navigating the challenges of a competitive and rapidly evolving biotechnology landscape.